mineralocorticoid receptor heart failure
HF is a chronic progressive condition in which the heart is unable to pump enough blood to meet organ/tissue requirements. Overall, these findings suggest that sex-specific therapies may be necessary to retard the aging process and improve cardiovascular disease outcomes in the aging population. Blockade of MR signaling with MR antagonists (MRAs) has been used clinically to treat kidney and cardiac disease associated with hypertension and other chronic diseases, resulting in suppression of fibrosis in these organs. Consequently, this leads to a decrease in blood pressure and a reduction in fluid around the heart. Clinically, mineralocorticoid receptor (MR) antagonists are widely prescribed for the treatment of hypertension and heart failure due to their diuretic action in the aldosterone-sensitive distal nephron. Summary By: Debabrata Mukherjee, MD, FACC Aldosterone receptor antagonists may be used in the treatment of high blood pressure or heart failure. Current treatment is primarily based on inhibition of hormones, mainly AngII, ALD, and catecholamines. However, the current use of steroidal … Mineralocorticoid receptor antagonists (MRAs) have been associated with improved patient outcomes in patients with heart failure with reduced ejection fraction (HFrEF) but not preserved ejection fraction (HFpEF). We determined MR expression in the failing heart to clarify the mechanism of action of aldosterone antagonist in the treatment of congestive heart failure. We conducted a systematic review and meta-analysis of selective and nonselective MRAs in HFrEF and HFpEF. It constitutes one of the most important global health problems. Mineralocorticoid receptors in smooth muscle cells play a significant role in cardiovascular aging in both sexes; however, they do so by distinct mechanisms. By blocking the effects of aldosterone, aldosterone receptor antagonists block the reabsorption of sodium, which encourages water loss. JAMA Cardiol 2016;Nov 14:[Epub ahead of print]. Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and We searched Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. Stress is increasingly associated with heart dysfunction and is linked to higher mortality rates in patients with cardiometabolic disease. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. Mineralocorticoid Receptor Activation and Heart Failure. Mineralocorticoid receptors (MRs) have been identified in the human cardiovascular tissues. MR … The rate of adverse events in practice has exceeded that foreshadowed by randomized controlled trials (RCTs). Introduction: Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant. Glucocorticoids are primary stress hormones that regulate homeostasis through two nuclear receptors, the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), both of which are present in cardiomyocytes. Hypertension and heart failure can be treated with mineralocorticoid-receptor antagonists, although therapy is associated with an increased incidence of hyperkalemia. Activation of the mineralocorticoid receptor (MR) plays important roles in both physiological and pathological events.